A comparison of δ9-THC and anandamide induced c-fos expression in the rat forebrain

Brain Research

Volumn 802, Issue 1-2, 1998, Pages 19-26

  McGregor, Iain S ^a   Arnold, Jonathon C ^a   Weber, Marianne F ^a   Topple, Ann N ^a   Hunt, Glenn E ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

9 THC; Anandamide; c fos; Cannabinoid; Hypothalamus; Rat

Indexed keywords

ANANDAMIDE; CANNABINOID RECEPTOR; DRONABINOL; RECEPTOR SUBTYPE;

AMYGDALOID NUCLEUS; ANIMAL TISSUE; ANXIETY; ARTICLE; BODY TEMPERATURE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG CROSS TOLERANCE; DRUG DISCRIMINATION; DRUG RECEPTOR BINDING; FOREBRAIN; IMMEDIATE EARLY GENE; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; ONCOGENE C FOS; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RAT; RECEPTOR OCCUPANCY; SECOND MESSENGER; THALAMUS MIDLINE NUCLEUS;

ANIMALS; ARACHIDONIC ACIDS; BODY TEMPERATURE; GENE EXPRESSION; MALE; MOTOR ACTIVITY; NEURONS; POLYUNSATURATED ALKAMIDES; PROSENCEPHALON; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR; TETRAHYDROCANNABINOL; TISSUE DISTRIBUTION;

EID: 0344813762     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00549-6     Document Type: Article

References (40)

1. M. Beltramo, N. Stella, A. Calignano, S.Y. Lin, A. Makriyannis, D. Piomelli, Functional role of high-affinity anandamide transport, as revealed by selective inhibition, Science 277 (1997) 1094-1097.
2. C.S. Breivogel, L.J. Sim, S.R. Childers, Regional differences in cannabinoid receptor G-protein coupling in rat brain, J. Pharmacol. Exp. Ther. 282 (1997) 1632-1642.
3. 9-THC in a drug-discrimination procedure, Exp. Clin. Psychopharmacol. 5 (1997) 195-202.
4. T.H. Burkey, R.M. Quock, P. Consroe, F.J. Ehlert, Y. Hosohata, W.R. Roeske, H.I. Yamamura, Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain, Eur. J. Pharmacol. 336 (1997) 295-298.
5. A.K. Cadogan, S.P. Alexander, E.A. Boyd, D.A. Kendall, Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum, J. Neurochem. 69 (1997) 1131-1137.
6. D.R. Compton, K.C. Rice, B.R. De Costa, R.K. Razdan, L.S. Melvin, M.R. Johnson, B.R. Martin, Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities, J. Pharmacol. Exp. Ther. 265 (1993) 218-226.
7. J.N. Crawley, R.L. Corwin, J.K. Robinson, C.C. Felder, W.A. Devane, J. Axelrod, Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents, Pharmacol. Biochem. Behav. 46 (1993) 967-972.
8. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, R. Mechoulam, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science 258 (1992) 1946-1949.
9. V. Di Marzo, A. Fontana, H. Cadas, S. Schinelli, G. Cimino, J.C. Schwartz, D. Piomelli, Formation and inactivation of endogenous cannabinoid anandamide in central neurons, Nature 372 (1994) 686-691.
10. G.E. Duncan, D.J. Knapp, G.R. Breese, Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety, Brain Res. 713 (1996) 79-91.
11. 9-tetra-hydrocannabinol, Brain Res. 697 (1995) 83-90.
12. E. Fride, R. Mechoulam, Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent, Eur. J. Pharmacol. 231 (1993) 313-314.
13. E.L. Gardner, J.H. Lowinson, Marijuana's interaction with brain reward systems: update 1991, Pharmacol. Biochem. Behav. 40 (1991) 571-580.
14. 9-tetrahydrocannabinol and the synthetic cannabinoid CP-55,940 induce expression of c-fos mRNA in stress-responsive nuclei of rat brain, Soc. Neurosci. Abstr. 20 (1994) 1676.
15. P. Hughes, M. Dragunow, Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system, Pharmacol. Rev. 47 (1995) 133-178.
16. M.H. Joseph, A.M.J. Young, J.A. Gray, Are neurochemistry and reinforcement enough? Can the abuse potential of drugs be explained by common actions on a dopamine reward system in the brain?, Hum. Psychopharmacol. 11 (1996) S55-S63.
17. P. Leff, C. Scaramellini, C. Law, K. McKechnie, A three-state receptor model of agonist action, TIPS 18 (1997) 355-362.
18. P. Mailleux, M. Verslype, X. Preudhomme, J.J. Vanderhaeghen, Activation of multiple transcription factor genes by tetrahydrocannabinol in rat forebrain, NeuroReport 5 (1994) 1265-1268.
19. 9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance, Life Sci., in press.
20. I.S. McGregor, Marijuana addiction (letter), Science 277 (1997) 749-750.
21. I.S. McGregor, F. Dastur, R.A. McLellan, R.E. Brown, Cannabinoid modulation of rat pup ultrasonic vocalizations, Eur. J. Pharmacol. 313 (1996) 43-49.
22. 9-tetrahydrocannabinol, Brain Res. 763 (1997) 137-140.
23. 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain, Brain Res. 710 (1996) 234-240.
24. S. Ohkura, C. Fabre-Nys, K.D. Broad, K.M. Kendrick, Sex hormones enhance the impact of male sensory cues on both primary and association cortical components of visual and olfactory processing pathways as well as in limbic and hypothalamic regions in female sheep, Neuroscience 80 (1997) 285-297.
25. 9-THC and cannabinoid (CB1) receptor gene expression in mice, Behav. Brain Res. 72 (1995) 115-125.
26. E.S. Onaivi, M.R. Green, B.R. Martin, Pharmacological characterization of cannabinoids in the elevated plus maze, J. Pharmacol. Exp. Ther. 253 (1990) 1002-1009.
27. S.R. Pagliusi, M. Tessari, S. DeVevey, C. Chiamulera, E.M. Pich, The reinforcing properties of nicotine are associated with a specific patterning of c-fos expression in the rat brain, Eur. J. Neurosci. 8 (1996) 2247-2256.
28. L.A. Parker, T. Gillies, THC-induced place and taste aversions in Lewis and Sprague-Dawley rats, Behav. Neurosci. 109 (1995) 71-78.
29. R.G. Pertwee, L.A. Stevenson, G. Griffin, Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55940, WIN 55212-2 and anandamide, Br. J. Pharmacol. 110 (1993) 1483-1490, [Published erratum appears in Br. J. Pharmacol. 1994 Mar; 111(3):968].
30. M. Puder, J. Weidenfeld, I. Chowers, I. Nir, N. Conforti, R.A. Siegel, Corticotrophin and corticosterone secretion following delta 1-Tetrahydrocannabinol, in intact and in hypothalamic deaf-ferentated male rats, Exp. Brain Res. 46 (1982) 85-88.
31. M. Rinaldi-Carmona, B. Calandra, D. Shire, M. Bouaboula, D. Oustric, F. Barth, P. Casellas, P. Ferrara, G. Lefur, Characterization of two cloned human CB1 cannabinoid receptor isoforms, J. Pharmacol. Exp. Ther. 278 (1996) 871-878.
32. F. Rodriguez de Fonseca, M.R.A. Carrera, M. Navarro, G.F. Koob, F. Weiss, Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal, Science 276 (1997) 2050-2054.
33. J. Romero, R. de Miguel, E. Garcia-Palomero, J.J. Fernandez-Ruiz, J.A. Ramos, Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function, Brain Res. 694 (1995) 223-232.
34. J.D. Salamone, M.S. Cousins, B.J. Snyder, Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis, Neurosci. Biobehav. Rev. 21 (1997) 341-359.
35. M.C. Sanudo-Pena, K. Tsou, E.R. Delay, A.G. Hohman, M. Force, J.M. Walker, Endogenous cannabinoids as an aversive or counter-rewarding system in the rat, Neurosci. Lett. 223 (1997) 125-128.
36. V.M. Showalter, D.R. Compton, B.R. Martin, M.E. Abood, Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands, J. Pharmacol. Exp. Ther. 278 (1996) 989-999.
37. G. Tanda, F.E. Pontieri, G. DI Chiara, Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism, Science 276 (1997) 2048-2050.
38. Z. Vogel, J. Barg, R. Levy, D. Saya, E. Heldman, R. Mechoulam, Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase, J. Neurochem. 61 (1993) 352-355.
39. J. Weidenfeld, S. Feldman, R. Mechoulam, Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat, Neuroendocrinology 59 (1994) 110-112.
40. J.L. Wiley, K.M. Golden, W.J. Ryan, R.L. Balster, R.K. Razdan, B.R. Martin, Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys, Pharmacol. Biochem. Behav. 58 (1997) 1139-1143.